COmpliance and Efficacy in Mono and Combination Tablet Study ATacand/Atacand Plus - Full Text View

COmpliance and Efficacy in Mono and Combination Tablet Study ATacand/Atacand Plus (COMBAT)

This study has been completed.

First Received: September 6, 2007 Last Updated: July 13, 2009 History of Changes

Sponsor:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00526279

Purpose

To evaluate compliance and patients' satisfaction in mono and combination treatment of Candesartan cilexetil (Atacand)/ Candesartan cilexetil 16mg, hydrochlorothiazide 12.5mg (Atacand plus) in hypertension.

Condition
Hypertension

Study Type:	Observational
Study Design:	Cohort, Prospective
Official Title:	A Prospective, Non-interventional, Observational, Multi-center Trial to Evaluate Compliance and Efficacy in Mono and Combination Treatment of Candesartan Cilexetil(Atacand)/ Candesartan Cilexetil 16mg, Hydrochlorothiazide 12.5mg(Atacand Plus) in Hypertension

Resource links provided by NLM:

MedlinePlus related topics: High Blood Pressure

Drug Information available for: CV 11974 Candesartan cilexetil

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Estimated Enrollment:	9000
Study Start Date:	July 2007
Study Completion Date:	August 2008

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

Primary Care

Criteria

Inclusion Criteria:

Patients who have consented to participation/data release in this study
Patients diagnosed with hypertension and prescribed with atacand/atacand plus by the physician based on clinical decision

Exclusion Criteria:

Secondary hypertension requiring therapy other than antihypertensive medication
Patients not prescribed with atacand/atacand plus based on safety reasons or any other reason as determined by the physician
Women in pregnancy or lactation
Patients enrolled in any other studies

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00526279

Locations

Korea, Republic of, Jongro-gu
Research Site
Seoul, Jongro-gu, Korea, Republic of
Korea, Republic of, Kangnam-gu
Research Site
Seoul, Kangnam-gu, Korea, Republic of
Korea, Republic of, Songpa-gu
Research Site
Seoul, Songpa-gu, Korea, Republic of

Sponsors and Collaborators

AstraZeneca

Investigators

Study Director:

Hyunah Caroline Choi

AstraZeneca Korea

More Information

Additional Information:

Related Info This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers:	NIS-CKR-ATA-2007/2
Study First Received:	September 6, 2007
Last Updated:	July 13, 2009
ClinicalTrials.gov Identifier:	NCT00526279 History of Changes
Health Authority:	Korea: Food and Drug Administration

Keywords provided by AstraZeneca:

Hypertension
Atacand/Atacand plus
COMBAT

Compliance
Naturalistic
Observational

Additional relevant MeSH terms:

Angiotensin II Type 1 Receptor Blockers
Candesartan cilexetil
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Candesartan
Vascular Diseases

Cardiovascular Diseases
Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions
Hypertension

ClinicalTrials.gov processed this record on February 08, 2010